Evidence map›Paper›PMID 36165100›Full record

ArticleJournal of cachexia, sarcopenia and muscle2022

A preponderance of gastrointestinal cancer patients transition into cachexia syndrome.

Linda Anne Gilmore, Santiago Olaechea, Brian W Gilmore, Bhavani S Gannavarapu, Christian M Alvarez, Chul Ahn, Puneeth Iyengar, Rodney E Infante

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 19 citations in OpenAlex.

  1. Defining Cachexia in Children With Cancer in the United States: Developing a Framework to Inform Clinical and Research Practice.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2026
    Article
  2. Article
  3. Undetected Weight Loss Associates With Upstaging in Cancer Patients.Journal of cachexia, sarcopenia and muscle · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Metabolic underpinnings of cancer-related fatigue.American journal of physiology. Endocrinology and metabolism · 2024
    Review
  14. Cancer cachexia research: coming of age.Translational lung cancer research · 2023
    Article
  15. Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities.Journal of the National Cancer Institute. Monographs · 2023
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Linda Anne GilmoreDepartment of Clinical Nutrition, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-2612-2538
Santiago OlaecheaCenter for Human Nutrition, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA.
Brian W GilmoreDepartment of Computer Science and Engineering, University of North Texas, Denton, TX, USA.
Bhavani S GannavarapuDepartment of Radiation Oncology, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA.
Christian M AlvarezDepartment of Clinical Nutrition, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA.
Chul AhnHarold C. Simmons Comprehensive Cancer Center, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA.
Puneeth IyengarCenter for Human Nutrition, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA.
Rodney E InfanteCenter for Human Nutrition, University of Texas (UT) Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-2605-822X
Southwestern Medical Center · USUniversity of North Texas · US

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI JAY D. HORTON · 2022 to 2026
$7.4M
UT Southwestern Center for Translational Medicine (UL18Kl2/TL1)TL1TR001104 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$418k
NIDDK NIH HHS P30 DK127984NIH HHS P30CA142543NIH HHS TL1TR001104NIH HHS UL1TR001105
6 · The paper itself

Abstract

backgroundCancer cachexia is frequently documented by self-reported, single time-point weight histories. This approach lacks the granularity needed to fully elucidate the progression of cachexia syndrome. This study aimed to longitudinally assess body weight changes pre- and post-cancer diagnosis in gastrointestinal (GI) cancer patients.

methodsBody weights and relevant clinical data recorded in the electronic health record 12 months pre- and post-GI cancer (colorectal, gastroesophageal, hepatobiliary and pancreatic) diagnosis were extracted. Weight loss was categorized by the International Consensus Definition for cachexia.

resultsA total of 879 patients were included in the final cohort including patients diagnosed with colorectal (n = 317), hepatocellular (n = 185), biliary (n = 72), pancreatic (n = 186) or gastroesophageal (n = 119) cancer. Stage of disease was equally distributed. Patients without cachexia at diagnosis (n = 608) remained weight stable during the 12 months pre-diagnosis (+0.5 ± 0.5% body weight; P = 0.99). Patients with cachexia at diagnosis (n = 271) remained weight stable 6 to 12 months prior to diagnosis (+0.4 ± 0.8%; P > 0.9999) and lost 8.7 ± 0.6% (P < 0.0001) within the 6 months pre-diagnosis. Patients without cachexia at diagnosis lost more weight post-diagnosis (6.3 ± 0.6%) than patients with cachexia at diagnosis (4.7 ± 1.0%; P = 0.01). Pre-diagnosis weight trajectories did not differ between primary malignancies or stage of disease in patients without or with cachexia at diagnosis (all P ≥ 0.05). Post-diagnosis weight trajectories did differ by primary malignancy (P ≤ 0.0002) and stage (P < 0.0001). In both patients without and with cachexia at diagnosis, colorectal patients lost the least amount of weight post-diagnosis and gastroesophageal patients lost the most amount of weight post-diagnosis. Stage 4 patients without or with cachexia at diagnosis lost the most weight post-diagnosis (P ≤ 0.0003). Regardless of cachexia status at diagnosis, patients lost more weight when treated with systemic therapy (7.1 ± 0.7%; P < 0.0001; n = 419) or radiation therapy (8.4 ± 1.4%; P = 0.02; n = 116) compared to those who did not. Patients who did not have surgery lost more weight post-diagnosis (7.6 ± 1.1%; P < 0.0001; n = 355) compared to those who did have surgery. By 12 months post-diagnosis, 83% of the surviving GI cancer patients in this cohort had transitioned into cachexia syndrome.

conclusionsSignificant weight loss in patients with GI cancer cachexia at diagnosis initiates at least 6 months prior to diagnosis, and most patients will transition into cachexia syndrome post-diagnosis, regardless of pre-diagnosis weight change and stage of disease. These findings punctuate the importance of weight surveillance in cancer detection and earlier palliative interventions post-diagnosis in the GI cancer patient population.

Indexed as

Body-Weight TrajectoryGastrointestinal NeoplasmsWasting SyndromeCachexiaHumansWeight Losscolorectal cancergastroesophageal cancerhepatobiliary cancerpancreatic cancerweight loss

Identifiers

PMID36165100
PMCPMC9745477
OpenAlexW4297256377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.